Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The DelVIN Trial - A Multicenter Phase I Trial Evaluating the Safety and Preliminary Efficacy of Local Decitabine Treatment of Human Papillomavirus (HPV)-Induced Vulvar Intraepithelial Neoplasia (VIN) Grade 2/3

NCT05717621 is registered in ClinicalTrials.gov with ViMREX GmbH as lead sponsor.

NCT NCT05717621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05717621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The DelVIN Trial - A Multicenter Phase I Trial Evaluating the Safety and Preliminary Efficacy of Local Decitabine Treatment of Human Papillomavirus (HPV)-Induced Vulvar Intraepithelial Neoplasia (VIN) Grade 2/3
Lead sponsor
ViMREX GmbH
Phase
Phase 1
Overall status
Completed
Start date
March 28, 2023
Completion date
January 17, 2025
Enrollment
29 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

vulvar intraepithelial neoplasia grade 2, vulvar intraepithelial neoplasia grade 3